Mediwound reports second quarter 2025 financial results and provides corporate update

Value phase iii trial of escharex ® in venous leg ulcers continues to enroll patients nexobrid ® manufacturing expansion on track; full operational capacity expected by year-end 2025 additional strategic research collaborations established with essity and convatec second quarter 2025 revenue of $5.7 million, up 43% from prior quarter conference call today, august 14, 2025, at 8:30am eastern time yavne, israel, aug. 14, 2025 (globe newswire) -- mediwound ltd. (nasdaq: mdwd), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended june 30, 2025, and provided a corporate update.
MDWD Ratings Summary
MDWD Quant Ranking